Semaglutide, NICE guidelines and diabetes: the key facts

You've been told semaglutide could help with your type 2 diabetes, but there are several products and you're not sure which applies

This is one of the most common points of confusion our prescribers encounter. Three different medicines contain semaglutide; they work through the same mechanism but at different doses, in different formulations, for different licensed purposes. Ozempic (0.5mg, 1mg or 2mg weekly injection) is licensed specifically for blood-sugar management in adults with type 2 diabetes. Rybelsus (3mg, 7mg and 14mg daily tablets) carries the same diabetes-only indication. Wegovy (a higher-dose weekly injection, escalating to 2.4mg) is licensed for weight management in adults with a BMI of 30 or above, or 27 and above alongside a weight-related condition.

NICE's appraisals reflect these separate licences. The diabetes recommendations sit in NICE's type 2 diabetes guidelines and technology appraisals for individual GLP-1 agents; the weight-management recommendation for Wegovy sits in TA875, published in March 2023. Knowing which pathway you're on matters because the prescribing criteria, the dose, the product and the clinical monitoring all differ. If your GP mentioned semaglutide in a diabetes context, they will almost certainly mean Ozempic or Rybelsus, and you can find a detailed breakdown of how semaglutide is used for diabetes on our dedicated overview page. If a weight-management clinic mentioned it, they likely mean Wegovy. You can read more about how Wegovy relates to type 2 diabetes specifically on our Wegovy and diabetes overview.

The misconception worth letting go gently here is that these are simply the same drug at different doses and therefore interchangeable. They are not, legally or clinically. Each product has its own MHRA marketing authorisation, its own dosing schedule, and its own set of NICE criteria. Swapping between them is a prescriber decision, not a self-management one.

What NICE TA875 actually says for people with type 2 diabetes seeking weight management support

NICE recommends Wegovy for weight management in adults with a BMI of 35 or above who also have at least one weight-related comorbidity, used within a specialist multidisciplinary service and for a maximum of two years. The threshold drops to 30–34.9 where specialist referral criteria are met. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under the same appraisal, the adjustment is 2.5 kg/m² throughout.

Type 2 diabetes is listed as one of the qualifying weight-related comorbidities, so people with both diabetes and obesity can, in principle, meet TA875 criteria for Wegovy. In practice this means referral to a specialist weight management service, a multidisciplinary assessment, and treatment embedded within a structured programme of dietary and activity support. NHS waiting lists for these services are substantial in many areas, which is why some people with type 2 diabetes explore the private route. The NHS medicines page for semaglutide sets out the general safety profile applicable to all semaglutide products.

One practical point worth knowing: if you are currently on Ozempic for diabetes and your weight is a separate clinical concern, moving to Wegovy is not automatic, it requires a fresh prescribing decision and, on the NHS, a referral pathway. A prescriber reviews both conditions together before any change is considered.

Safety considerations when diabetes and weight management intersect

For people managing type 2 diabetes, adding a higher-dose semaglutide for weight management introduces some additional monitoring considerations. Blood-glucose levels and, where relevant, existing diabetes medication doses may need reviewing, particularly if you take insulin or a sulfonylurea, medicines that carry a hypoglycaemia risk. This is a conversation for your diabetes team and your prescriber to have together, not something to adjust independently.

The general GI side-effect profile of semaglutide applies regardless of indication: nausea, diarrhoea, constipation and indigestion are most likely in the early weeks and after dose increases. They tend to ease as the body adjusts, but they can affect blood-sugar management temporarily if eating is disrupted. Pancreatitis is a less common but more serious risk; the MHRA Drug Safety Update index carries the relevant communications for clinicians and patients.

Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive, and if you have questions about how Wegovy can interact with pregnancy tests you may want to read our page on whether Wegovy can give you a false positive pregnancy test. If any of those situations apply to you, speak to your GP or diabetes specialist before starting or continuing treatment. The position on type 1 diabetes is also clear: semaglutide in any form is not licensed for type 1, and the evidence base for using it off-label in that setting is limited and carries specific risks around diabetic ketoacidosis. Our page on semaglutide and type 1 diabetes covers that question separately.

Accessing semaglutide for weight management when you also have type 2 diabetes, NHS and private routes

On the NHS, the route to Wegovy for weight management runs through specialist services, as TA875 specifies. If you have type 2 diabetes, your GP may be able to initiate a referral, but approval depends on meeting the full criteria and local commissioning arrangements. If you are weighing up whether semaglutide is the right option for your type 2 diabetes, our dedicated page walks through the clinical considerations in detail. NHS England is rolling out tirzepatide (Mounjaro) in primary care under a phased programme with overlapping eligibility criteria; your GP can advise whether that pathway is open to you locally.

For the private route, a regulated online pharmacy can offer a consultation for Wegovy if you meet the licensed criteria, BMI 30 or above, or 27 and above with a weight-related condition, which type 2 diabetes satisfies. That consultation must involve a real prescriber reviewing your health history, current medications and diabetes management before any prescription is issued. At nume, every consultation is read by a GPhC-registered Independent Prescriber, and transfer patients or those with complex conditions receive particularly careful clinical review. Our Wegovy overview sets out what a private consultation covers and what happens at each stage. If you'd like to explore whether Wegovy is appropriate for your situation, you can check your eligibility through a free, no-obligation consultation.